SUMMARY OF PRODUCT CHARACTERISTICS

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Nobilis Multriva RT+IBm+ND+EDS emulsion for injection for chickens

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each dose of 0.3 ml contains:

Active substances:

Avian metapneumovirus, strain BUT1 #8544, inactivated	≥ 19.0 U[1]
Infectious bronchitis virus, strain M41, inactivated	≥ 4.8 $\log_2$ HI[2]
Infectious bronchitis virus, strain 4/91, inactivated	≥ 5.7 $\log_2$ HI[2]
Newcastle disease virus, strain Ulster, inactivated	≥ 5.9 U[1]
Egg drop syndrome 1976 virus, strain BC14, inactivated	≥ 368.3 U[1]

[1] As determined in an *in vitro* antigenic mass ELISA potency test
[2] HI = hemagglutination inhibition. As determined in an *in vivo* potency test in chickens by hemagglutination inhibition

Adjuvant:

Light liquid paraffin	128.6 mg

Excipients:

Qualitative composition of excipients and other constituents
Polysorbate 80
Sorbitan oleate
PBS solution

Homogeneous, (nearly) white emulsion.

3. CLINICAL INFORMATION

3.1 Target species

Chickens.

3.2 Indications for use for each target species

For the active immunisation of chickens for:
- reduction of egg drop caused by avian metapneumovirus (AMPV);
- reduction of respiratory signs and egg drop caused by infectious bronchitis virus (IBV) strains Massachusetts (GI-1 genotype) and 4/91-793B;
- reduction of mortality and clinical signs caused by Newcastle disease virus (NDV);

▪ reduction of egg drop and eggshell defects caused by egg drop syndrome 1976 virus (EDSV).

Onset of immunity:
- IBV, NDV and EDSV: 4 weeks post-vaccination;
- AMPV: 5 weeks post-vaccination;

Duration of immunity:
AMPV, IBV, NDV and EDSV: 80 weeks post-vaccination.

3.3 Contraindications

None.

3.4 Special warnings

Vaccinate healthy animals only.

3.5 Special precautions for use

Special precautions for safe use in the target species:
Not applicable.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:
To the user:
This veterinary medicinal product contains mineral oil. Accidental injection/self-injection may result in severe pain and swelling, particularly if injected into a joint or finger, and in rare cases could result in the loss of the affected finger if prompt medical attention is not given. If you are accidentally injected with this veterinary medicinal product, seek prompt medical advice even if only a very small amount is injected and take the package leaflet with you. If pain persists for more than 12 hours after medical examination, seek medical advice again.

To the physician:
This veterinary medicinal product contains mineral oil. Even if small amounts have been injected, accidental injection with this veterinary medicinal product can cause intense swelling, which may, for example, result in ischaemic necrosis and even the loss of a digit. Expert, PROMPT, surgical attention is required and may necessitate early incision and irrigation of the injected area, especially where there is involvement of finger pulp or tendon.

Special precautions for the protection of the environment:
Not applicable.

3.6 Adverse events

Chickens:

Uncommon (1 to 10 animals / 1,000 animals treated):	Injection site lump[1]

[1] Generally disappearing within 3 weeks. Maximum size of the swelling up to 3 cm in diameter.

Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or the national competent authority via the national reporting system. See the package leaflet for respective contact details.

3.7 Use during pregnancy, lactation or lay

Laying birds:
Do not use in birds in lay and within 4 weeks before the start of the laying period.

3.8 Interaction with other medicinal products and other forms of interaction

No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product. A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be made on a case-by-case basis.

3.9 Administration routes and dosage

This vaccine is intended for use as a booster vaccination following priming with either live or inactivated vaccines in the vaccination schedule. Primary vaccinations should be performed with live or inactivated vaccines against infectious bronchitis virus (e.g. Nobilis IB 4/91, Nobilis IB Ma5). The vaccine should be given at least 4 weeks after administration of the primary vaccination.

For intramuscular use.

Administer a single dose of 0.3 ml in the breast or thigh region from 8 weeks of age onwards, but no later than 4 weeks before the onset of lay.

Before use, allow the vaccine to reach room temperature.
Shake well before use.
Syringes and needles must be sterile before use.
Follow standard aseptic procedures.

When primary vaccinations were performed against avian metapneumovirus (e.g. Nobilis Rhino CV) and/or Newcastle disease virus (e.g. Nobilis ND C2, Nobilis ND Clone 30, Innovax-ND-IBD), the vaccine should be given at least 4 weeks after administration of the primary vaccination.

3.10 Symptoms of overdose (and where applicable, emergency procedures and antidotes)

No adverse reactions other than those mentioned in section 3.6 were observed after the administration of a two-fold overdose of vaccine.

3.11 Special restrictions for use and special conditions for use, including restrictions on the use of antimicrobial and antiparasitic veterinary medicinal products in order to limit the risk of development of resistance

Not applicable.

3.12 Withdrawal periods

Zero days.

4. IMMUNOLOGICAL INFORMATION

ATCvet code: QI01AA18.

The vaccine is intended to stimulate active immunity against avian rhinotracheitis virus, infectious bronchitis virus, Newcastle disease virus and egg drop syndrome 1976 virus.

A cross protection study showed reduction of respiratory signs caused by IBV strain Var 2 (GI-23 genotype) and a reduction of egg drop for IBV strains QX-D388 (GI-19 genotype), Q1 (GI-16 genotype) and Var2 (GI-23 genotype). For these strains no onset of immunity or duration of immunity was established.

5. PHARMACEUTICAL PARTICULARS

5.1 Major incompatibilities

Do not mix with any other veterinary medicinal product.

5.2 Shelf life

Shelf life of the veterinary medicinal product as packaged for sale: 2 years.
Shelf life after first opening the immediate packaging: 10 hours.

5.3 Special precautions for storage

Store in a refrigerator (2 °C – 8 °C).
Do not freeze.
Protect from direct sunlight.

5.4 Nature and composition of immediate packaging

Bottle of polyethylene terephthalate (PET) closed with a rubber stopper and aluminium cap.

Pack sizes:
Cardboard box with 1 bottle of 300 ml (1,000 doses) or 600 ml (2,000 doses).
Not all pack sizes may be marketed.

5.5 Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products

Medicines should not be disposed of via wastewater or household waste.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any national collection systems applicable to the veterinary medicinal product concerned.

6. NAME OF THE MARKETING AUTHORISATION HOLDER

MSD Animal Health UK Limited

7. MARKETING AUTHORISATION NUMBER

Vm 01708/5125

8. DATE OF FIRST AUTHORISATION

16 January 2026

9. DATE OF THE LAST REVISION OF THE SUMMARY OF THE PRODUCT CHARACTERISTICS

January 2026

10. CLASSIFICATION OF VETERINARY MEDICINAL PRODUCT

Veterinary medicinal product subject to prescription.

Find more product information by searching for the ‘Product Information Database’ on www.gov.uk.

Gavin Hall
Approved: 15 April 2026